Cargando…
Direct AMPK Activation Corrects NASH in Rodents Through Metabolic Effects and Direct Action on Inflammation and Fibrogenesis
No approved therapies are available for nonalcoholic steatohepatitis (NASH). Adenosine monophosphate–activated protein kinase (AMPK) is a central regulator of cell metabolism; its activation has been suggested as a therapeutic approach to NASH. Here we aimed to fully characterize the potential for d...
Autores principales: | Gluais‐Dagorn, Pascale, Foretz, Marc, Steinberg, Gregory R., Batchuluun, Battsetseg, Zawistowska‐Deniziak, Anna, Lambooij, Joost M., Guigas, Bruno, Carling, David, Monternier, Pierre‐Axel, Moller, David E., Bolze, Sebastien, Hallakou‐Bozec, Sophie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8710801/ https://www.ncbi.nlm.nih.gov/pubmed/34494384 http://dx.doi.org/10.1002/hep4.1799 |
Ejemplares similares
-
Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: A phase 1b study
por: Fouqueray, Pascale, et al.
Publicado: (2021) -
Reduced lactic acidosis risk with Imeglimin: Comparison with Metformin
por: Theurey, Pierre, et al.
Publicado: (2022) -
Imeglimin preserves islet β‐cell mass in Type 2 diabetic ZDF rats
por: Hallakou‐Bozec, Sophie, et al.
Publicado: (2020) -
Deuterium‐Stabilized (R)‐Pioglitazone (PXL065) Is Responsible for Pioglitazone Efficacy in NASH yet Exhibits Little to No PPARγ Activity
por: Jacques, Vincent, et al.
Publicado: (2021) -
Dendritic cell–intrinsic LKB1-AMPK/SIK signaling controls metabolic homeostasis by limiting the hepatic Th17 response during obesity
por: vanderZande, Hendrik J.P., et al.
Publicado: (2023)